Abstracts tagged "ANCA"

Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Pierre Charles¹, Agnes Dechartres ², Benjamin Terrier ³, Pascal Cohen ³, Stanislas Faguer ⁴, Antoine Huart ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Bernard Bonnotte ⁶, Maxime Samson ⁷, Alexandre Karras ⁸, Noémie Jourde-Chiche ⁹, François Lifermann ¹⁰, Pierre Gobert ¹¹, Catherine Hanrotel-Saliou ¹², Pascal Godmer ¹³, Nicolas Martin-Silva ¹⁴, Grégory Pugnet ¹⁵, Marie Matignon ¹⁶, Olivier Aumaitre ¹⁷, Jean-François Viallard ¹⁸, François Maurier ¹⁹, Nadine Meaux Ruault ²⁰, Sophie Rivière ²¹, Jean Sibilia ²², Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³ and Loic Guillevin ³, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁴CHU Toulouse, Toulouse, France, ⁵CHU Nantes, Nantes, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷CHU Dijon, Dijon, France, ⁸Paris HEGP, Paris, France, ⁹APHM, Marseille, Marseille, France, ¹⁰CH Dax, Dax, France, ¹¹CH Avignon, Avignon, France, ¹²CHU Brest, Brest, France, ¹³CH Bretagne-Atlantique, Vannes, France, ¹⁴CHU Caen, Caen, France, ¹⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁶APHP, Créteil, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Bordeaux, Bordeaux, France, ¹⁹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ²⁰CHU Besançon, Besançon, France, ²¹CHU Montpellier, Montpellier, France, ²²CHU Strasbourg, Strasbourg, France
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…
Abstract Number: 2627 • 2019 ACR/ARP Annual Meeting
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Shinya Hirahara¹, Yasuhiro Katsumata ¹, Ken-ei Sada ², Hiroko Nagafuchi ³, Eiichi Tanaka ¹ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kitaku, Okayama, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Background/Purpose: Chronic inflammatory diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) substantially affects patients’ daily lives, including their ability to work. Although the management…
Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…
Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Paul Brogan¹, Gavin Cleary², Aimee O. Hersh³, Ozgur Kasapcopur⁴, Satyapal Rangaraj⁵, Rae S.M. Yeung⁶, Andrew Zeft⁷, Simone Melega⁸, Paul Brunetta⁹, Jennifer Cooper¹⁰, Pooneh Pordeli¹¹ and Patricia B. Lehane¹², ¹Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Alder Hey Children's Hospital, Liverpool, United Kingdom, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁶Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, ¹¹Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…
Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, François Lifermann⁴, Loïk Geffray⁵, Thomas Quémeneur⁶, Jean-Luc Saraux⁷, Marie Wislez⁸, Vincent Cottin⁹, Marc Ruivard¹⁰, Nicolas Limal¹¹, Achille Aouba¹², Bernard Bonnotte¹³, Antoine Neel¹⁴, Christian Agard¹⁵, Pascal Cohen¹⁶, Benjamin Terrier¹⁷, Claire Le Jeunne¹⁷, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹⁷, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hôtel Dieu, Paris, France, ⁴Dax, Dax, France, ⁵Lisieux, Lisieux, France, ⁶Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁷Eaubonne, Eaubonne, France, ⁸Paris Tenon, Paris, Gambia, ⁹Lyon Louis Pradel, Lyon, France, ¹⁰Clermont-Ferrand, Clermont Ferrand, France, ¹¹Créteil Henri Mondor, Créteil, France, ¹²Caen, Caen, France, ¹³Dijon, Dijon, France, ¹⁴Medecine Interne, Nantes Hôtel Dieu, Nantes, France, ¹⁵Nantes Hôtel Dieu, Nantes, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
Abstract Number: 1967 • 2018 ACR/ARHP Annual Meeting
Detection of Association of Long Noncoding RNA ATP6V0E2-AS1 Single Nucleotide Polymorphism with Susceptibility to Myeloperoxidase-ANCA Associated Vasculitis Based on Transcriptome Analysis
Yuka Iwahashi^1,2, Aya Kawasaki^1,2, Takayo Tsuchiura³, Ken-ei Sada⁴, Fumio Hirano^5,6, Daisuke Tsukui⁷, Shigeto Kobayashi⁸, Hidehiro Yamada⁹, Hiroshi Furukawa^1,2,10, Kenji Nagasaka¹¹, Takahiko Sugihara¹², Nao Nishida³, Kunihiro Yamagata¹³, Takayuki Sumida¹⁴, Shigeto Tohma^10,15, Shoichi Ozaki⁹, Hiroshi Hashimoto¹⁶, Hirofumi Makino¹⁷, Yoshihiro Arimura¹⁸, Hajime Kono¹⁹, Masayoshi Harigai²⁰ and Naoyuki Tsuchiya^1,2, ¹University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ²University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ³Genome Medical Science Project, National Center for Global Health and Medicine, Research Center for Hepatitis and Immunology, Ichikawa, Japan, ⁴Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁵Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁶Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁷Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁸Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁹St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ¹⁰National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ¹¹Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹³University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ¹⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁵National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹⁶Juntendo University School of Medicine, Tokyo, Japan, ¹⁷Okayama University Hospital, Okayama, Japan, ¹⁸Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ¹⁹Teikyo University School of Medicine, Department of Internal Medicine, Tokyo, Japan, ²⁰Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: Because of the low prevalence, only three genome-wide association studies, all from the Caucasian populations, have been reported on ANCA-associated vasculitis (AAV) thus far;…
Abstract Number: 2738 • 2018 ACR/ARHP Annual Meeting
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Peter A. Merkel¹, David Jayne², Thomas J. Schall³, Pirow Bekker³ and Jan Hillson³, ¹Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³ChemoCentryx, Mountain View, CA
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPeter A. Merkel1, David…
Abstract Number: 1748 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA-Positive Vasculitis Patients
Andy Abril¹, Minkyung Kwon,², Isabel Mira-Avendano³, Carlos Rojas⁴ and Andras Khoor⁵, ¹Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²Pulmonary and Critical Care, Mayo Clinic, Jacksonville, FL, ³Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, FL, ⁴Radiology, Mayo Clinic, Jacksonville, FL, ⁵Pathology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Rarely, ANCA-positive vasculitis patients are found to have interstitial lung disease (ILD). Clinical characteristics and prognosis are not well known in these patients. The…
Abstract Number: 2440 • 2018 ACR/ARHP Annual Meeting
Outcomes of Pregnancy Complicated By ANCA-Associated Vasculitis: A Retrospective Review
Jennifer Strouse¹, Melissa Swee², Manish Suneja¹ and Bharat Kumar³, ¹Internal Medicine, University of Iowa, Iowa City, IA, ²Transplant Nephrology, University of Iowa, Iowa City, IA, ³Internal Medicine-Division of Immunology, University of Iowa, Iowa City, IA
Background/Purpose: ANCA-Associated Vasculitis (AAV) is a small-vessel vasculitis that predominantly affects the kidneys, lungs, and sinuses, among other organs. It has been traditionally associated with…
Abstract Number: 2739 • 2018 ACR/ARHP Annual Meeting
Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
Luciano Fernando Lo Giudice¹, Marina Scolnik², Jose Maximiliano Martinez P³, Aurelia Luissi¹, Valeria Scaglioni² and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The glucocorticoid toxicity index (GTI) (Miloslavsky et al. Ann Rheum Dis 2017) is useful to assess impact on morbility associated with these drugs. It…
Abstract Number: 1750 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Titer Is Inversely Correlated with ANCA Titer and Relates to Characteristic Manifestations in Patients with Eosinophilic Granulomatosis with Polyangiitis
Jun Inamo, Yuko Kaneko, Yuichiro Ota and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), which is characterized by vasculitis with allergic features such as…
Abstract Number: 2718 • 2018 ACR/ARHP Annual Meeting
Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort
Yasuhiro Katsumata¹, Ken-ei Sada², Tomohiro Kameda³, Hiroaki Dobashi³, Hisashi Yamanaka⁴ and Masayoshi Harigai⁵, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan, ³Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: In 2017, the multicenter European Vasculitis Study Group (EUVAS) evaluated the diagnostic accuracy of a wide spectrum of detection tests of MPO and PR3-ANCAs…
Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting
Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation
Yusuke Miyazaki¹, Shingo Nakayamada¹, Satoshi Kubo¹, Kazuhisa Nakano¹, Shigeru Iwata², Shunsuke Fukuyo³, Akio Kawabe⁴ and Yoshiya Tanaka⁵, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…
Abstract Number: 1751 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor
Thibault Maillet¹, Tiphaine Goletto², Guillaume Beltramo³, Henry Dupuy⁴, Stéphane Jouneau⁵, Raphaël Borie⁶, Bruno Crestani⁶, Vincent Cottin⁷, Daniel Blockmans⁸, Estibaliz Lazaro⁴, Jean-Marc Naccache⁹, Grégory Pugnet¹⁰, Hilario Nunes¹¹, Mathilde De Menthon¹², Hervé Devilliers¹³, Philippe Bonniaud³, Xavier Puéchal¹⁴, Luc Mouthon¹⁴, Bernard Bonnotte¹, Loïc Guillevin¹⁵, Benjamin Terrier¹⁴ and Maxime Samson¹, ¹Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France, ²Service de Pneumologie, Hôpital Saint-Louis, APHP, Paris, France, ³Service de Pneumologie, CHU de Dijon, Dijon, France, ⁴Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, Bordeaux, France, ⁵Service de Pneumologie, CHU de Rennes; IRSET UMR 1085, Université de Rennes 1, Rennes, France, ⁶Service de Pneumologie, Hôpital Bichat, APHP, Paris, France, ⁷Service de Pneumologie, Hôpital Louis-Pradel, Bron, France, ⁸Rheumatology, UZ Leuven, Leuven, Belgium, ⁹Service de Pneumologie, Hôpital Tenon, APHP, Paris, France, ¹⁰Service de Médecine Interne, CHU de Toulouse, Toulouse, France, ¹¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ¹²Service de Médecine Interne, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France, ¹³Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹⁴Centre de Référence des Maladies Auto-immunes et Systémiques Rares, Vascularites Nécrosantes et Sclérodermie Systémique, Service de Médecine Interne, Hôpital Cochin, APHP, INSERM U1016, Université Paris Descartes, Paris, France, ¹⁵Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Interstitial lung disease (ILD), rarely described in ANCA-associated vasculitis (AAV) patients, was mainly associated with anti-MPO ANCA. ILD’s prognostic value remains unclear. This study…

« Previous Page
1
…
6
7
8
9
10
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].